Shares of bluebird bio (NASDAQ: BLUE) rose over 16% last month, according to data from S&P Global Market Intelligence. The biopharma reported fourth-quarter and full-year 2018 operating results. As a pre-commercial company, there wasn't much in the way of financial numbers to review, although the business did begin 2019 with $1.9 billion in cash, cash equivalents, and marketable securities.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,